302 related articles for article (PubMed ID: 32707446)
1. Landscape of circulating tumour DNA in metastatic breast cancer.
Davis AA; Jacob S; Gerratana L; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Cristofanilli M
EBioMedicine; 2020 Aug; 58():102914. PubMed ID: 32707446
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
Davis AA; Gerratana L; Clifton K; Medford AJ; Velimirovic M; Hensing WL; Bucheit L; Shah AN; D'Amico P; Reduzzi C; Zhang Q; Dai CS; Denault EN; Bagegni NA; Opyrchal M; Ademuyiwa FO; Bose R; Gradishar WJ; Behdad A; Ma CX; Bardia A; Cristofanilli M
EBioMedicine; 2022 Dec; 86():104316. PubMed ID: 36332363
[TBL] [Abstract][Full Text] [Related]
3. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
[TBL] [Abstract][Full Text] [Related]
4. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M
Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406
[TBL] [Abstract][Full Text] [Related]
5. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
6. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
8. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
[TBL] [Abstract][Full Text] [Related]
10. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R
Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636
[TBL] [Abstract][Full Text] [Related]
11. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
12. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
[TBL] [Abstract][Full Text] [Related]
13. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
14. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Gerratana L; Davis AA; Velimirovic M; Clifton K; Hensing WL; Shah AN; Dai CS; Reduzzi C; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Puglisi F; Ma CX; Bardia A; Cristofanilli M
Breast Cancer Res; 2023 Oct; 25(1):112. PubMed ID: 37784176
[TBL] [Abstract][Full Text] [Related]
15. Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
Gerratana L; Davis AA; Polano M; Zhang Q; Shah AN; Lin C; Basile D; Toffoli G; Wehbe F; Puglisi F; Behdad A; Platanias LC; Gradishar WJ; Cristofanilli M
Eur J Cancer; 2021 Jan; 143():147-157. PubMed ID: 33307492
[TBL] [Abstract][Full Text] [Related]
16. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
17. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.
Page K; Martinson LJ; Fernandez-Garcia D; Hills A; Gleason KLT; Gray MC; Rushton AJ; Nteliopoulos G; Hastings RK; Goddard K; Ions C; Parmar V; Primrose L; Openshaw MR; Guttery DS; Palmieri C; Ali S; Stebbing J; Coombes RC; Shaw JA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34849446
[TBL] [Abstract][Full Text] [Related]
19. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers.
Okamura R; Kurzrock R; Mallory RJ; Fanta PT; Burgoyne AM; Clary BM; Kato S; Sicklick JK
Int J Cancer; 2021 Feb; 148(3):702-712. PubMed ID: 32700810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
